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in Ventricular Assist Device Patients?*
Peter M. Eckman, MDA trial ﬁbrillation (AF) management poseschallenges that are typically distilled into asimple question: rate control or rhythm con-
trol? Do the beneﬁts of full anticoagulation outweigh
the potential risks in this patient? As an internal med-
icine resident, I found AF management much less
anxiety provoking than acute coronary syndromes.
Hours of pathophysiology and lurking in the back
of the room on rounds reinforced the relatively
“benign” nature of AF. The AFFIRM (Atrial Fibrilla-
tion Follow-up Investigation of Rhythm Manage-
ment) study was published (1), I used the CHADS2
(congestive heart failure, hypertension, age, diabetes
mellitus, prior stroke or TIA or thromboembolism)
score (2), and learned how to address the simple
questions. AF was quickly ﬁled under “phone calls
that I can handle alone.”
My conﬁdence in managing AF was short-lived.
There is nothing like practicing medicine to remind
you on a daily basis how much you have yet to learn.
AF is a common comorbidity in patients with heart
failure (HF), and examples of AF triggering an acute
HF decompensation were never hard to ﬁnd, sug-
gesting that maybe AF patients with concurrent HF
should be treated differently. The AF-CHF (Atrial
Fibrillation–Congestive Heart Failure) trial tested the
hypothesis that AF prevention would improve sur-
vival in patients with HF with reduced ejection frac-
tion but failed to ﬁnd an advantage to a rhythm*Editorials published in the Journal of the American College of Cardiology
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Minnesota).control strategy (3). However, it is hard to ignore the
appeal of rhythm control, and we now place our
hopes in a catheter-based rhythm control strategy
(4). Results from prospective randomized trials such
as RAFT-AF (A Randomized Ablation-based Atrial
Fibrillation Rhythm Control Versus Rate Control Trial
in Patients with Heart Failure and High Burden Atrial
Fibrillation, NCT01420393) and CASTLE-AF (Catheter
Ablation Versus Standard Conventional Treatment
in Patients With Left Ventricular Dysfunction and
Atrial Fibrillation, NCT00643188) are eagerly antici-
pated but could be our next helpings of humble pie.
At least I did not have to worry too much about
AF in my ventricular assist device (VAD) patients. All
received anticoagulation therapy, and the relative
importance of atrial function appeared inconsequen-
tial compared to the liters of ﬂow that mechanical
circulatory support can provide, nourishing previ-
ously ﬂow-starved tissues and organs. Ventricular
arrhythmias command a greater share of our atten-
tion, and if patients with VADs can tolerate ven-
tricular ﬁbrillation (5), one might assume that if it
is hard to show an advantage to rhythm control in
HF patients, it would be even harder to observe a
difference in the VAD population. Finally, compared
to the challenges of balancing risks of hemorrhage
and thrombus in VADs, AF in this population was
much lower on the priority list. Despite the fre-
quency of AF in HF patients undergoing a VAD
implant procedure, little has been published in this
area, highlighting a gap in our understanding.SEE PAGE 1883In this issue of the Journal, Enriquez et al. (6) have
helped close this gap by reporting their study of the
effect of AF in 106 patients who received aHeartMate II
(Thoratec, Pleasanton, California) VAD. Most of the
population (88%) received VAD implantations with
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1892the intention of acquiring a bridge to transplantation,
and approximately 50% of patients had AF prior to
implantation, a factor previously associated with
increased risk of thromboembolic (TE) events after
VAD (7). It is difﬁcult to ﬁnd clear data for the preva-
lence of AF in patients undergoing VAD implantation
and appears to be on the high end. Of the 55 AF patients
in this study, it was present prior to VAD implantation
in all but 5, a number small enough to preclude deﬁn-
itive conclusions about the risk of adverse events
following newly developed AF after HeartMate II
implantation. Only 3 patients underwent surgical
treatment (Cryo-Maze [Medtronic, Minneapolis, Min-
nesota] or left atrial appendage [LAA] ligation) that
was presumed to have an impact on event risk.
Although the anticoagulation regimen for patients
without AF was lower (international normalized ratio
[INR] goal of 1.5 to 2) than that used currently by most
programs with HeartMate II, it was a common regimen
during the study period, reﬂecting previously pub-
lished data (8). Overall, although this report is from a
single center, the subject population is reasonably
comparable to that previously described receiving the
VAD as a bridge to transplantation,with the potentially
notable exception that the patients with AF in the
present studywere older (paroxysmal: 59.4 9.8 years
of age; persistent: 61.0  8.3 years of age) than those
in the HeartMate II bridge-to-transplantation trial
(50.1  13.1 years of age) (9).
The lack of associations among paroxysmal AF
and mortality, HF hospitalization, bleeding, and TE
events is reassuring, although a minor effect cannot
be deﬁnitively excluded in this relatively small pop-
ulation. This ﬁnding suggests that any hemodynamic
effect of intermittent AF in the HeartMate II popula-
tion is likely to be minimal and that conventional
anticoagulation is appropriate for this group.
The most notable ﬁnding, however, was that
persistent AF was an independent predictor of death
or HF hospitalization in patients who received a VAD
in this study. The effect was stronger for HF hospi-
talization (hazard ratio [HR]: 7.37; p < 0.01) and
barely missed achieving statistical signiﬁcance for
mortality (HR: 2.65; p ¼ 0.06). In Figure 1 in the
Enriquez et al. article (6), it appears to be approxi-
mately 75 days after implantation that the groups
diverge, a time point at which the greatest risks of
implantation such as acute right ventricular failure
have passed. Can we, perhaps, speculate about the
mechanism by which persistent AF appears to affect
outcomes based on this time of divergence? Inability
to fully engage in rehabilitation due to poor exercise
tolerance, borderline right ventricular function, and
ventricular arrhythmias are often prominent issuesat 1 to 2 months after implantation. We could hy-
pothesize that persistent AF would lead to more
aggressive use of beta blockers, which could impair
right ventricular function and chronotropic response.
It is unfortunate (although typical) that only 35 pa-
tients in this cohort had cardiopulmonary testing
after VAD implantation, a group size that is under-
powered to draw conclusions about the impact of AF
on exercise capacity, much less begin to attribute
impairment to any speciﬁc factor, such as use of a
speciﬁc class of medications. Comparison between
individual exercise test results of paroxysmal AF pa-
tients and those of sinus rhythm patients might
help to further our understanding of the mechanism
by which persistent AF impacts outcomes. Unfortu-
nately, reviewing the causes of death (Table 3 in
the Enriquez et al. article [6]) does not provide a
very satisfying clue to the mechanism for possibly
increased risk of mortality, as the suggestion of
increased risk of death from sepsis in the persistent
AF group is hard to attribute to AF burden.
Another important ﬁnding was that TE events in
patients with AF occurred despite a higher INR at the
time of event, as shown in Figure 4 in the Enriquez
et al. article (6). Alternatively, this study’s ﬁnding
could be taken as evidence that the risk of TE com-
plications is very low in the absence of AF and
the presence of INR >2. Because the single TE event
observed in the persistent AF group could be a
consequence of the sample size, it raises the question
of whether the mechanism of TE events (especially
neurologic) in the VAD population is the same as in
patients with natural circulation. For example, if
we presume that emboli originated in the LAA and
that most blood ﬂows through the VAD, we would
expect the debris that would navigate the device and
arrive in the cerebral vasculature to be quite small.
The smallest gap in the HeartMate II, for example, is
approximately 0.003 inches, according to the manu-
facturer. Altered ﬂow in the ascending aorta from
the outﬂow graft might also be expected to alter the
cerebral distribution of infarctions, even if throm-
boemboli escape the heart through the aortic valve.
We also might expect thrombi to form in the proximal
aorta from stasis resulting from infrequent opening
of the aortic valve, which would be expected to be
independent of AF.
Should patients who receive a VAD and have AF
have a more aggressive INR goal, such as 2.0 to 3.0
rather than 2.0 to 2.5? Optimizing anticoagulation in
the VAD population to minimize morbidity and mor-
tality remains one of the “holy grails” of mechanical
circulatory support and must be balanced against the
increased risk of bleeding. The risk of fatal
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1893intracranial hemorrhage in this study was approxi-
mately 4% (2 of 55 patients) in the AF group and zero
in the group of patients without AF, highlighting the
potential cost to more aggressive anticoagulation.
Validation of these ﬁndings in larger cohorts and
additional centers would be important before advo-
cating signiﬁcant changes in the anticoagulation
protocols currently recommended. Another impor-
tant consideration that this study raises is whether
we should pursue a rhythm control strategy in VAD
patients with AF. The limitations of pharmacologic
therapy to maintain sinus rhythm are well known.
The risk-beneﬁt proﬁle of pulmonary vein isolation in
patients with VAD is completely unknown, but these
ﬁndings tantalize us once again with the hope that
rhythm control will be the superior strategy. A trial
of the role of surgical treatment (LAA ligation, con-
current Cox maze procedure) at the time of VAD im-
plantation would have ample justiﬁcation. It alsomight advance our understanding of the mechanism
of cerebrovascular infarction in the VAD population,
if such a trial were negative, implying that the path-
ophysiology of infarction from AF in this group may
indeed be different.
Enriquez et al. (6) have identiﬁed an important
signal that persistent AF in the CF-VAD population
portends increased risk of HF hospitalization and,
potentially, mortality. This should stimulate addi-
tional work to help the ﬁeld understand the me-
chanisms, which may help us understand the
consequences of AF in the much larger population
who do not have a VAD.
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